Xvivo Perfusion ABXVIPF -1.32%91 Days Inventory is 310.82 as of Mar. 2026, which is 4% below its 10-year median of 323.78. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 786 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 86.26% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's Days Inventory or its related term are showing as below:
XVIPF'
s Days Inventory Range Over the Past 10 Years
Min: 235.85 Med: 323.78 Max: 408.46
Current: 408.46
During the past 13 years, Xvivo Perfusion AB's highest Days Inventory was 408.46. The lowest was 235.85. And the median was 323.78.
XVIPF's Days Inventory is ranked worse than 86.26% of 786
companies
in the Medical Devices & Instruments industry
Industry Median: 179.86
vs XVIPF: 408.46
Xvivo Perfusion AB's Days Inventory
declined
from Mar. 2025 (341.44) to Mar. 2026 (310.82).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Xvivo Perfusion AB's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.29.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xvivo Perfusion AB's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.99.
Xvivo Perfusion AB (OTCPK:XVIPF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Xvivo Perfusion AB's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xvivo Perfusion AB's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Xvivo Perfusion AB Days Inventory Related Terms
Xvivo Perfusion AB Days Inventory Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Days Inventory vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Days Inventory of 310.82 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xvivo Perfusion AB and its competitors. This is near median its historical median of 323.78. Over the past decade, Xvivo Perfusion AB's Days Inventory has ranged from 235.85 to 408.46. According to the industry distribution chart, Xvivo Perfusion AB ranks #678 out of 786 companies in the Medical Devices & Instruments industry, placing it in the top 86.3%.
Is Xvivo Perfusion AB's Days Inventory too high?
Xvivo Perfusion AB's current Days Inventory of 310.82 is near median its 10-year median of 323.78. Over the past 10 years, this metric has ranged from a low of 235.85 to a high of 408.46. The Medical Devices & Instruments industry median Days Inventory is 179.86. Xvivo Perfusion AB's value of 310.82 is 72.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #678 out of 786 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Days Inventory compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #678 out of 786 companies for Days Inventory. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Days Inventory is 179.86. Xvivo Perfusion AB's value of 310.82 is 72.8% above this benchmark. Historically, Xvivo Perfusion AB's own Days Inventory has ranged from 235.85 to 408.46 over the past decade. While the company's 10-year median is 323.78 vs. the industry median of 179.86, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Devices & Instruments company?
The median Days Inventory among Medical Devices & Instruments companies is 179.86, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Days Inventory of 310.82 is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Days Inventory is 179.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Days Inventory is 310.82, which is near median its own 10-year median of 323.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Days Inventory is 310.82, which is near median its 10-year median of 323.78 and 72.8% above the Medical Devices & Instruments industry median of 179.86. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Days Inventory is 310.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Days Inventory: 310.82 (near median its 10-year median of 323.78)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 72.8% above the Medical Devices & Instruments median (#678 of 786)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
